EUVIMEDEUVIMED entdecken
Crossref

Discovery and optimization of N-phenylbenzenesulfonamide analogues as novel ALKBH5 inhibitors for AML therapy

Qiuting Xu, Shuying Xie, Jiachen Wei, Qinkuai Wu, Meng Xiao, Yike Ma, Hailang Xu, Wenxiu Wang, Xicheng Chen, Xiaoke Gu, Mingshan Niu, Jingying Qiu

Bioorganic Chemistry · 2026-11 · 184 · 110658

DOI: 10.1016/j.bioorg.2026.110658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Qiuting Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Antineoplastic Agents, AlkB Homolog 5, RNA Demethylase. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Jiangsu Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is an aggressive malignancy with poor prognosis, primarily driven by leukemic stem cells (LSCs). The RNA demethylase ALKBH5 is aberrantly overexpressed in AML and critically involved in leukemogenesis and LSC maintenance. Herein, we designed and synthesized fifty-seven N-phenylbenzenesulfonamide derivatives as potential ALKBH5 inhibitors. Within this series, G4 emerged as a potent ALKBH5 inhibitor that selectively suppressed ALKBH5-high AML cells over ALKBH5-knockout cells and normal human PBMCs. In G4-treated AML cells, cell cycle arrest and apoptosis were accompanied by dose-dependent reductions in MCL-1 and Bcl-xL protein levels. Genetic knockout of ALKBH5 markedly attenuated G4-induced cytotoxicity, supporting the ALKBH5 dependence of G4 activity. CETSA and SPR further supported a direct interaction between G4 and ALKBH5. MD simulations and 2-OG competition assays suggested the involvement of the 2-OG pocket in G4 recognition. Mechanistically, G4 directly inhibited ALKBH5 and elevated global m6A levels. Consistently, G4 dose-dependently downregulated TACC3, a known ALKBH5 target, impaired LSC self-renewal, and showed significant in vivo anti-AML efficacy. Collectively, these findings identify G4 as an ALKBH5 inhibitor that impairs LSCs self-renewal with robust in vivo efficacy, providing a promising lead for further optimization toward AML therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesAntineoplastic AgentsAlkB Homolog 5, RNA DemethylaseEnzyme InhibitorsDrug DiscoveryHumansStructure-Activity RelationshipDose-Response Relationship, DrugAnimalsMolecular StructureDrug Screening Assays, AntitumorCell ProliferationMiceApoptosisBenzenesulfonamides

Stichwörter der Autor:innen

ALKBH5 inhibitorAML therapyLSCsN-phenylbenzenesulfonamide

Substanzen

SulfonamidesAntineoplastic AgentsAlkB Homolog 5, RNA DemethylaseALKBH5 protein, humanEnzyme InhibitorsBenzenesulfonamides

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
  • Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China; Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. Electronic address: gu_xk@xzhmu.edu.cn.
  • Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China; Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. El…
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. Electronic address: jingyqiu@xzhmu.edu.cn.

Förderung

  • Jiangsu Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Xu, Q., Xie, S., Wei, J., Wu, Q., Xiao, M., Ma, Y., Xu, H., Wang, W., Chen, X., Gu, X., Niu, M., & Qiu, J. (2026). Discovery and optimization of N-phenylbenzenesulfonamide analogues as novel ALKBH5 inhibitors for AML therapy. Bioorganic Chemistry, 184, 110658. https://doi.org/10.1016/j.bioorg.2026.110658

Vancouver

Xu Q, Xie S, Wei J, Wu Q, Xiao M, Ma Y, et al. Discovery and optimization of N-phenylbenzenesulfonamide analogues as novel ALKBH5 inhibitors for AML therapy. Bioorganic Chemistry. 2026;184:110658. doi:10.1016/j.bioorg.2026.110658

BibTeX
@article{Xu2026,
  author = {Xu, Qiuting and Xie, Shuying and Wei, Jiachen and Wu, Qinkuai and Xiao, Meng and Ma, Yike and Xu, Hailang and Wang, Wenxiu and Chen, Xicheng and Gu, Xiaoke and Niu, Mingshan and Qiu, Jingying},
  title = {Discovery and optimization of N-phenylbenzenesulfonamide analogues as novel ALKBH5 inhibitors for AML therapy},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {184},
  pages = {110658},
  doi = {10.1016/j.bioorg.2026.110658}
}
Kostenlos starten →